BreastScreening-AI Company Profile

Background

Overview

BreastScreening-AI is a Portugal-based company specializing in the development of advanced artificial intelligence (AI) systems for the early detection of breast cancer. By integrating multiple imaging modalities—including mammograms, MRI scans, and ultrasound images—the company aims to enhance diagnostic accuracy and efficiency in clinical settings.

Mission and Vision

The company's mission is to leverage AI technology to accurately diagnose breast cancer, thereby eliminating medical errors and significantly improving patient outcomes. BreastScreening-AI envisions a future where early breast cancer detection is accessible, accurate, and efficient for healthcare providers worldwide.

Primary Area of Focus

BreastScreening-AI focuses on developing AI-powered diagnostic tools that analyze multimodal breast imaging data to assist clinicians in early breast cancer detection. The integration of various imaging modalities enables the AI system to process information comprehensively, enhancing diagnostic precision.

Industry Significance

In the healthcare sector, particularly in oncology, early detection of breast cancer is crucial for effective treatment and improved survival rates. By providing AI-driven diagnostic assistance, BreastScreening-AI contributes to reducing false positives and negatives, thereby streamlining healthcare processes and enhancing patient care.

Key Strategic Focus

Core Objectives

• Enhancing Diagnostic Accuracy: Develop AI systems that improve the precision of breast cancer detection through advanced image analysis.

• Reducing Medical Errors: Implement AI tools to minimize diagnostic errors, leading to better patient outcomes.

• Streamlining Healthcare Efficiency: Integrate AI solutions into clinical workflows to optimize time and resource utilization.

Specific Areas of Specialization

• Multimodal Imaging Analysis: Utilize AI to analyze and interpret data from various imaging modalities, including mammography, ultrasound, and MRI.

• AI Integration in Clinical Workflows: Design AI systems that seamlessly integrate with existing clinical processes to support radiologists and clinicians.

Key Technologies Utilized

• Multimodal Convolutional Neural Networks (MMCNNs): Employ deep learning models capable of processing and analyzing multiple imaging modalities simultaneously.

• Explainable AI: Develop AI systems that provide transparent and understandable outputs to foster trust among healthcare professionals.

Primary Markets Targeted

• Healthcare Providers: Hospitals, clinics, and diagnostic centers seeking advanced diagnostic tools.

• Radiologists and Clinicians: Medical professionals requiring reliable AI assistance for breast cancer detection.

Financials and Funding

Funding History

BreastScreening-AI has secured funding from various sources, including Startup Lisboa and the Fundação para a Ciência e a Tecnologia.

Total Funds Raised

The company has raised between €100K and €500K to support its research and development efforts.

Notable Investors

• Startup Lisboa: A Lisbon-based startup accelerator supporting innovative companies.

• Fundação para a Ciência e a Tecnologia: A Portuguese public agency that funds science and technology initiatives.

Intended Utilization of Capital

The raised funds are allocated towards the development of AI algorithms, clinical validation studies, and integration of AI systems into clinical workflows to enhance breast cancer detection capabilities.

Pipeline Development

Key Pipeline Candidates

• Multimodal AI Diagnostic Tool: An AI system capable of analyzing mammograms, MRI scans, and ultrasound images to assist in early breast cancer detection.

Stages of Development

• Research and Development: Ongoing efforts to refine AI algorithms and integrate them with clinical imaging systems.

• Clinical Validation: Conducting studies to validate the accuracy and reliability of AI-driven diagnostic tools in real-world clinical settings.

Target Conditions

• Breast Cancer: Focusing on the early detection and diagnosis of breast cancer through advanced imaging analysis.

Anticipated Milestones

• Clinical Trials: Initiating trials to assess the performance of AI diagnostic tools in diverse clinical environments.

• Regulatory Approvals: Seeking necessary certifications and approvals for AI systems to be used in medical diagnostics.

Technological Platform and Innovation

Proprietary Technologies

• Multimodal Convolutional Neural Networks (MMCNNs): Deep learning models designed to process and interpret data from various imaging modalities simultaneously.

Significant Scientific Methods

• Explainable AI: Developing AI systems that provide transparent and understandable outputs to foster trust among healthcare professionals.

• Human-AI Interaction Studies: Conducting research to understand and improve the interaction between clinicians and AI systems, ensuring effective collaboration.

Leadership Team

Key Executives

• Francisco Maria Calisto: CEO and founder, with expertise in user research and healthcare technology.

• Carlos Santiago: Lead AI, specializing in artificial intelligence applications in medical imaging.

• Jacinto Nascimento: Computer Vision Advisor, focusing on computer vision techniques for medical image analysis.

• Nuno Nunes: User Research Advisor, emphasizing user-centered design in healthcare technology.

Leadership Changes

No significant leadership changes have been reported recently.

Competitor Profile

Market Insights and Dynamics

The breast cancer imaging market is experiencing significant growth, driven by technological advancements in AI and increasing demand for early detection methods. The U.S. breast cancer imaging market, for instance, is projected to reach USD 1,012.17 million by 2033, growing at a CAGR of 7.42% from 2025 to 2033.